Lilly to present more than 50 studies at ASCO meeting

INDIANAPOLIS Eli Lilly & Co. will unveil more than 50 studies at the 45th annual meeting of the American Society of Clinical Oncology in Orlando Fla., the drug maker announced Tuesday.

The company said most of the studies it will present at the meeting, which will take place from May 29 to June 2, will deal with its thoracic cancer research, such as the latest research findings on Alimta (pemetrexed) and Gemzar (gemcitabine hydrochloride), as well as the investigational drug enzastaurin. The company will also feature the newest molecules in its portfolio resulting from its acquisition of ImClone Systems.

“ASCO’s theme of ‘Personalizing Cancer Care’ is one to which Lilly has subscribed for many years,” Lilly VP cancer research and global oncology platform leader Richard Gaynor said in a statement. “We are focused on delivering what we call ‘tailored therapies’ – an essential component of personalized medicine – to identify patients who are most likely to respond to therapy, and just as importantly, which patients will not.”